Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer (ADCT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- US stock futures tumble as Trump says Iran deal is 'over', oil climbs
- Oil jumps over 6% to two-week high after Trump says deal with Iran 'over'
- Citi says SpaceX stock has path to $900+ valuation. Here’s how
- Tesla stock target lifted at RBC on potential SpaceX merger
- Short squeezes more likely than widespread selling: Citi
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer
April 6, 2021 7:00 AM EDTSenior pharmaceutical executive with deep oncology experience in Asia formerly of Takeda, MSD, Bayer and Pfizer
BOSTON, SHANGHAI & LAUSANNE, Switzerland--(BUSINESS WIRE)-- Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals and ADC Therapeutics SA (NYSE: ADCT), today announced the appointment of Eric Koo, BSc, MBA, as Chief Executive Officer. Mr. Koo brings more than 25 years of pharmaceutical industry and business management experience to Overland ADCT BioPharma with a proven track record of executing successful drug approvals and launches across Asia.
This press... More
